Please login to the form below

Not currently logged in
Email:
Password:

solanezumab

This page shows the latest solanezumab news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

BACE inhibitors are designed to block the formation of the amyloid plaques that characterise the disease, unlike earlier antibody drugs such as Lilly’s solanezumab and Pfizer’s bapineuzumab which attempted ... candidate, which works in a slightly

Latest news

More from news
Approximately 9 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Lilly said that while the study results, ‘including many secondary clinical endpoints, directionally favoured solanezumab, the magnitudes of treatment differences were small’. ... December, where Lilly confirmed it will not pursue regulatory

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Lilly's great hope in amyloid beta is now solanezumab, a candidate with a chequered history. ... But Lilly is pressing on with a third late-stage trial, and Dr Hutton was adamant solanezumab remains a priority project for Lilly.

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics